Ceapro Inc V.CZO

Another solid quarter

[Ciao]

Besides great growth in their active ingredients contributing to a 25% increase in q2 rev and EPS of .02, another potential catalyst will be the bioavailability study results due by the end of September.

[lscfa]

Q1 eps $0.03....Q2 eps $0.02....          US Germany China Other Canada Total Q2 22 3,837,675 1,132,572 514,327 11,125 4,700

[prophetoffactz]

The University of Alberta is studying PGX-Alginate/CoQ10, PGX-YBG/CoQ10, and PGX-Alginate-YBG/CoQ10. In today's news release the following was mentioned as we wait for results.    "Of interest, the size of PGX processed YBG particles (around 5 microns) would allow them to be “swallowable” by macrophages that would carry them to remote sites in the body. Thus, the loading

[Ciao]

I noticed the term Trojan Horse, that's a very significant term for drug delivery https://www.cellgs.com/blog/trojan-horses-in-therapeutics--half-way-through-the-city-gate.html

[Ciao]

From the link and the significance of macrophages: Another Trojan horse, not yet in clinical trials but steadily gaining more attention as potential delivery vehicles, are macrophages. The inherent homing capabilities of these immune cells to reach damaged, infected or malignant tissue, make them perfect candidates for the directed delivery of drugs in small concentrations, which could lower the

[prophetoffactz]

By combining PGX-YBG with PGX-Alginate, for instance, to get PGX-YBG-Alginate, CZO could also combine the delivery capabilities of both PGX-YBG and PGX-Alginate into a single treatment. CZO's recent alginate-CoQ10 news release pointed to the possibility of additional potent delivery systems. "While PGX-processed alginate is poised to become a key commercial strategic asset for the

[prophetoffactz]

I don't see any mention of the Angiogenesis Foundation collaboration. It was to be one year and one year since the deal was announced was yesterday. Interesting results may be reported in a quarterly report to tie up lose ends, etc. Important results may require its own news release. Maybe they still need more time. Ceapro Inc. Enters into Research Collaboration with the Angiogenesis

[prophetoffactz]

"Results from animal studies are being analyzed as part of a PhD thesis." During the recent interview Gilles wanted to get something out this summer. No timeline in todays news release. The bioavailability data is expected next month. Health Canada was on a 90 day clock for approval of the avenanthramide trial and today's news release anticipates approval in Q4.

[Ciao]

Here's some background on the work at McMaster for fibrosis; https://macsphere.mcmaster.ca/handle/11375/27162 [url=https://healthsci.mcmaster.ca/home/2021/11/11/mcmaster's-research-team-discovers-new-mechanism-to-reprogram-macrophages-for-potential-fibrotic-disease-and-covid-19-therapiy]https://healthsci.mcmaster.ca/home/2021/11/11/mcmaster's-research-team-discovers-new-mechanism-to